Introduction
============

Lung cancer is the most common cause of cancer related death. Alterations of sequence or structure of genes and their expression have an important role in the pathogenesis of lung cancer. Fusion genes and alternative splicing of cancer-related genes have the potential to gain oncogenic activity.

Fusion genes can potentially be used for lung cancer diagnosis, prognosis, and therapy. *EML4-ALK* fusion gene gains oncogenic activity by fusing two genes, one that has a role as a dimerization factor and other as a tyrosine kinase, and the oncogenic activity can be prevented by a kinase inhibitor[@B1]. Recent advances in sequencing technology enabled analysis of genetic changes, and there already has been several data reported related to lung cancer using the sequencing technology[@B2][@B3].

The recent developments of next-generation sequencing allow for increased base coverage of a DNA sequence, as well as higher sample throughput. This has facilitated the reconstruction of the entire transcriptome by deep RNA sequencing (RNA-seq), even without a reference genome[@B4]. It provides the ability to look at alternative gene spliced transcripts, posttranscriptional modifications, gene fusion, mutations/single-nucleotide polymorphism, and changes in gene expression.

Alternative splicing of cancer-related genes can affect cell cycle control, signal transduction pathway, apoptosis, angiogenesis, invasion, and metastasis[@B5]. Five different types of alternative splicing affect the resulting translated protein products[@B6]. Recent advance in RNA-seq provides the opportunity to quantitatively study alternative splicing[@B7]. Splice isoform can also be a therapeutic target[@B8].

In the current study, we performed RNA-seq to investigate potential oncogenic alternative splicing and fusion genes in 86 pairs of tissue samples from non-small cell lung cancer and normal lung.

Materials and Methods
=====================

1. Preparation of tissue samples
--------------------------------

This study included tissues obtained from the Biobank of Asan Medical Center (Seoul, Korea) donated by 88 male smokers who underwent surgery for non-small cell lung carcinoma (NSCLC) between March 2008 and March 2011. All of the paired NSCLC and adjacent normal tissue specimens used in this study were acquired from surgical specimens. Cancer and normal tissue specimens were grossly dissected and preserved in liquid nitrogen immediately after surgery. All protocols were approved by the Institutional Review Board of Asan Medical Center (2011-0711) and Kangwon National University Hospital (2011-04-004).

Resected tumor specimens were evaluated by routine frozen section procedures. The study samples were snap-frozen and stored at -80℃. Tumor and normal lung tissues were selected by a pathologist using manual microdissection under an inverted microscope.

For RNA-Seq, we extracted RNA from tissue using an RNeasy 96 Universal Tissue Kit (Qiagen, Gaithersburg, MD, USA). Total RNA quality and quantity were verified spectrophotometrically (NanoDrop 1000 Spectrophotometer; Thermo Scientific, Wilmington, DE, USA) and electrophoretically (Bioanalyzer 2100; Agilent Technologies, Palo Alto, CA, USA). To construct Illumina-compatible libraries, a TruSeq RNA Library Preparation Kit (Illumina, San Diego, CA, USA) was used according to the manufacturer\'s instructions. In brief, messenger RNA purified from total RNA using polyA selection was chemically fragmented and converted into single-stranded cDNA using random hexamer priming. Double-stranded (ds) cDNA was generated for TruSeq library construction. Short ds-cDNA fragments were joined with sequencing adapters, and suitable fragments were separated by agarose gel electrophoresis. TruSeq RNA libraries constructed by polymerase chain reaction (PCR) amplification were quantified using quantitative PCR (qPCR) according to the qPCR Quantification Protocol Guide, and their quality was assessed electrophoretically (Bioanalyzer 2100; Agilent Technologies). Sequencing was performed using a HiSeq 2000 platform (Illumina).

2. Fusion gene screening and validation
---------------------------------------

To discover gene fusion from RNA-seq data, we used DeFuse version 0.4.3 and ChimeraScan version 0.4.5[@B9][@B10].

In order to validate fusion transcript by Sanger sequencing, fusion candidate were selected. Fusion transcripts were observed only in cancer tissues, and protein coding transcripts were selected. Genes that were reported in cancer gene database (COSMIC, ChimerDB 2.0) and previous studied were validated.

For Sanger sequencing, 2 µg of total RNA was used for cDNA synthesis with an oligo-dT primer and PrimeScript reverse transcription polymerase chain reaction Kit (Takara, Kyoto, Japan) according to the manufacturer\'s protocol.

Fusion gene specific primer pairs and TAKARA Ex-Taq polymerase (Takara) were used for the PCR reaction. After purification, PCR products were sequenced with the BigDye Terminator v3.1 Sequencing Kit and a 3730xl automated sequencer (Applied Biosystems, Foster City, CA, USA). All DNA sequenced comparison alignments were performed using DNAstar SeqMan program (DNAstar, Madison, WI, USA).

3. Alternative splicing detection
---------------------------------

To estimate alternative spliced transcripts, the RNA-seq reads were mapped to the human genome using TopHat version 1.3.3[@B11]. Alternative splicing events were detected using MATS 3.0.6[@B12]. The statistical model calculated the p-value and false discovery rate by the Benjamini-Hochberg method that the difference in the isoform ratio of a gene between two conditions.

Results
=======

Demographic characteristics of subjects are listed ([Table 1](#T1){ref-type="table"}). A total of 86 subjects participated; all were male. Fifty-three were diagnosed with adenocarcinoma and 33 with squamous cell carcinoma (SqCC). The average age of subject was 61.1±9.4 and the average of smoking pack-year was 34.5±17.5. All analysis was processed in normal-cancer paired tissue samples.

1. Fusion gene
--------------

In the fusion gene analysis, 86 samples were analyzed using DeFuse and 33 SqCC samples were analyzed using both DeFuse and ChimeraScan. To identify expressed fusion-genes, we used DeFuse and ChimeraScan. From the RNA-seq data, 1,293 and 6,455 fusion transcripts were detected by the two different programs, respectively. Two *EML4-ALK*s and one *SLC34A2-ROS1* fusion gene, already known to be oncogenic, were detected in analysis result of DeFuse[@B1][@B2].

From these results, one *EML4-ALK* and one *SLC34A2-ROS1* fusion genes were validated by Sanger sequencing. Also according to our procedure, four fusion transcripts were selected ([Table 2](#T2){ref-type="table"}). The frequencies of the selected fusion transcripts were detected in 1%--5% of all samples. The four fusion transcripts were validated by Sanger sequencing ([Figure 1](#F1){ref-type="fig"}).

2. Alternative splicing
-----------------------

In the alternative splicing analysis, 33 SqCC samples were analyzed among the 86 samples. To identify alternative splicing events, total reads and reads aligned of alternative splicing were determined ([Table 3](#T3){ref-type="table"}).

There were 37 differential skipped exon events and six mutually exclusive exon events in the cancer samples compared to the normal samples. Also from these results, we found CD44 and vascular endothelial growth factor A, which were already known as alternative spliced genes, to exist in the cancer samples, and the most significant gene was CD44 ([Table 4](#T4){ref-type="table"})[@B5][@B13]. As a result of comparing the normal-cancer individual paired samples, there were 12,069 differential skipped exon events. To obtain selective list, 12,069 events were filtered with a condition (normal sample SE count, 0; tumor sample SE count, ≥10; and SE covering sample, ≥30), then 29 differential skipped exon events were selected. In the list of the selected genes, there were *ITBG4* and *PYCR1* outstanding genes and the most significant gene is *ITGB4* ([Table 4](#T4){ref-type="table"}).

Discussion
==========

In the current study, we have identified candidate fusion genes and alternative splicing in non-small cell lung cancer.

In the present study, *EML4-ALK* was detected with DeFuse, whereas it was not detected with ChimeraScan. DeFuse is more focused on finding breakposition of fusion candidates and applies various statistical methods and database to filter out fusion candidates, while ChimeraScan concentrates more on finding genes of fusion candidates. Therefore, transcripts from DeFuse were mainly used and those from ChimeraScan were used complementally. One *EML4-ALK* fusion gene and one *SLC34A2-ROS1* fusion gene were detected only in our cancer samples and not detected in the normal samples.

Potential candidate fusion transcripts identified in the present study are *AL137145.2-PFKFB3*, *C4orf3-KLHL2*, *TPPPBRD9*, and *HNRNPA2B1-SKAP2*. *AL137145.2-PFKFB3* fusion was detected with the highest percentage in four samples among the 86 cancer samples (4.7%). According to NCBI, SMART and Ensemble database, AL137145.2 was discovered simply as a protein coding gene and has not been identified clearly yet. 6-Phosphofructo-2-kinase (PFKFB3) has a PGAM domain which is involved with the transfer of phosphorous groups. There are no reports on fusion of PFKFB3. However, there has been many previous studies that show tumor growth is suppressed by the inhibition of PFKFB3 activity[@B14][@B15]. Therefore, it is possible to formulate the hypothesis that changes in *PFKFB3* by fusing with *AL137145.2* could be involved with cancer. *C4orf3-KLHL2* fusion was found in two samples out of the 86 cancer samples. Kelch-like protein 2 (KLHL2) consists of BTB/POS, BACK, and repeated Kelch domains. These domains were involved in evolution and ubiquitination, and they are known to be associated with cancer[@B16]. *C4orf3-KLHL2* fusion transcript could possess oncogenic activity by changes in the KLHL2 domain. *TPPP-BRD9* and *HNRNPA2B1-SKAP2* were detected in 1.2% of the total samples (1 out of 86), and the two fusions were found by both programs. In the case of *TPPP-BRD9*, there are no outstanding studies about tubulin polymerization promoting protein (*TPPP*) and bromodomain-containing protein 9 (*BRD9*) fusion. However, bromodomain family is used as a target of cancer therapy. BRD4 was reported to have a role in breast cancer progression and metastasis[@B17]. *TPPP-BRD9* fusion transcript was constructed by combining exon1 of *BRD9* with exon 11 of *TPPP* .

Heterogeneous nuclear ribonucleoprotein A2/B1 (*HNRNPA2B1*) of the *HNRNPA2B1-SKAP2* fusion transcript was found to fuse with several other partner genes such as *ETV1, AUTS2, PRR13,* and *SMARCA2* to form cancer-related fusion genes in COSMIC and ChimerDB2.0[@B18]. Similar to these reports, our results from RNA-seq showed *HNRNPA2B1* fused with different gene partners, such as src kinase associated phosphoprotein 2 (*SKAP2*), nuclear factor, erythroid 2-like 3 (*NFE2L3*), and pterin-4-alpha-carbinolamine dehydratase 2 (*PCBD2*). SKAP2 was reported to negatively regulate cell migration and tumor invasion in fibroblasts and glioblastoma cells[@B19]. *HNRNPA2B1-SKAP2* was organized by fusing exon 5 of *SKAP2* next to exon 8 of *HNRNPA2B1*. This configuration is the form that included all key domains as RNA recognition motif and sarcoma homology 3 domain. Therefore, *HNRNPA2B1-SKAP2* may have the potential to be a fusion gene of cancer.

In the alternative splicing of this study, exon 6 or 12 skipped CD44 and exon 6 or 7 skipped vascular endothelial growth factor (VEGF), which are already known splicing variants, were identified. Many previous studies have investigated the roles of various CD44 isoforms associated with cancer. Banky et al.[@B20] reported the roles of CD44 according to alternative splice patterns that were detected not only in colorectal tumor but also in other tumor tissues. CD44 isoforms, containing variable protein domain v3 and v6, have a role in metastasis and affects metastatic development. Correlation exists between tumor progression and higher expression levels of variable protein domain v3 and v6 in quantitative assessment[@B20]. VEGF is a regulator of angiogenesis and is strongly involved in cancer. Zygalaki et al.[@B21] studied previously about the correlation between its expression pattern and clinic-pathological characteristics of tumors. Exon 6 or 7 skipped VEGFA splice variants were detected in our analysis result, which is the same as prior reports.

This study discovered novel splice variant forms of *ITGB4* (integrin, beta 4) and pyrroline 5-carboxylate reductase 1 (*PYCR1*). ITGB4 is known to be over-expressed in tumor cells and has a role in metastasis[@B22]. Also, *ITGB4* was found to skip exon 35 in about half of patient samples[@B23]. Exon 18, 19, 33, or 34 skipped *ITGB4* splice variants were found in our samples. Skipping of exon 18, 19, and 34 were novel variant forms. Jariwala et al.[@B24] reported that *PYCR1* is one of the novel androgen receptor target genes in prostate cancer. However, alternative splicing of *PYCR1* was not reported in lung cancer. *PYRC1* exon 2 or 3 skipped *PYCR1* splice variants were detected in this study, and the exon 2 skipped form was a novel variant form.

A limitation of the current study is a lack of a functional study. Oncogenic potential of fusion transcripts and the role of alternative splicing should be investigated in the future.

In conclusion, novel potential fusion transcripts and splice variants were identified in NSCLC. Their functional significance in the pathogenesis of lung cancer should be evaluated.
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###### Baseline characteristics of the subjects

![](trd-79-85-i001)

  Characteristic             Value (n=86)
  -------------------------- --------------------
  Male:Female                86:0
  Age, yr                    61.1±9.4 (43--81)
  Smoking pack year, yr      34.5±17.5 (10--90)
  Histological type          
   Adenocarcinoma            53 (61.6)
    Stage I                  35 (40.7)
    Stage II                 18 (20.9)
    Stage III                None
   Squamous cell carcinoma   33 (38.4)
    Stage I                  9 (10.5)
    Stage II                 22 (25.6)
    Stage III                2 (2.3)

Values are presented as mean±standard deviation (range) or number (%).

###### The list of fusion transcripts from RNA sequencing and validation results of fusion by Sanger sequencing

![](trd-79-85-i002)

  Fusion gene           Frequency in RNA sequencing (n=86)   Frequency in Sanger sequencing (n=86)   p-value
  --------------------- ------------------------------------ --------------------------------------- ---------
  *EML4-ALK*            2 (2.3)                              1 (1.2)                                 0.560
  *SLC34A2-ROS1*        1 (1.2)                              1 (1.2)                                 \>0.999
  *PFKFB3-AL137145.2*   4 (4.7)                              4 (4.7)                                 \>0.999
  *KLHL2-C4orf3*        3 (3.5)                              2 (2.3)                                 0.650
  *TPPP-BRD9*           3 (3.5)                              1 (1.2)                                 0.312
  *HNRNPA2B1-SKAP2*     1 (1.2)                              1 (1.2)                                 \>0.999

Values are presented as number (%).

The t tests were used to confirm statistical significance between RNA and Sanger sequencing.

###### Statistics based on per group analysis using Burrows-Wheeler Alignment for paired-end reads
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  Sample   Total alignment                             
  -------- ----------------- ------------ ------------ ---------
  Normal   50,590,052        42,607,206   37,569,185   258,633
  Tumor    49,743,632        42,318,389   37,636,657   299,863

Reads AlignedTo DiffChr (mapQ≥5): the number of passing the sequence of vendor\'s filter reads that are aligned with mapping score ≥5 to the different chromosomes.

###### The list of alternative spliced genes between normal and cancer groups from skipped exon event

![](trd-79-85-i004)

  Gene symbol   Accession No.   Total exon   SE order   Tumor SE count   Junction type
  ------------- --------------- ------------ ---------- ---------------- ---------------
  *CD44*        NM_001001389    17           6          \-               Known
  *CD44*        NM_001001389    17           12         \-               Known
  *CD44*        NM_001202555    10           6          \-               Known
  *CD44*        NM_001001389    17           6          \-               Known
  *VEGFA*       NM_003376       8            6          \-               Known
  *VEGFA*       NM_001025366    8            7          \-               Known
  *ITGB4*       NM_001005731    39           34         22               Novel
  *ITGB4*       NM_001005619    39           33         22               Known
  *ITGB4*       NM_001005731    39           18         15               Novel
  *ITGB4*       NM_001005731    39           19         15               Novel
  *PYCR1*       NM_006907       7            3          16               Known
  *PYCR1*       NM_006907       7            2          16               Novel

SE: skipped exon.
